

**REMARKS**

Claim 71 has been amended.

New Claim 77 has been added. Support for the new claim can be found on page 293 of the specification.

**Rejection pursuant to 35 USC § 112, second paragraph**

Claims 71-76 are rejected under 35 USC § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the applicant regards as the invention.

Claim 71 has been amended to depend from Claim 38.

In view of this amendment, it is believed that this rejection has been overcome. Applicants respectfully request withdrawal of this rejection.

**Conclusion**

Claim 71 has been amended. It is believed that the claims are in condition for allowance, and it is respectfully requested that the application be passed to issue.

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, he is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,



Julie M. Lappin, Reg. No. 46,612

Pharmacia Corporation  
of Pfizer, Inc  
P.O. Box 1027  
Chesterfield, MO 63006  
(314) 274-2009  
(314) 274-9095 (facsimile)